Literature DB >> 14615453

Risk model predictive of severe anemia requiring RBC transfusion after chemotherapy in pediatric solid tumor patients.

Perrine Marec-Berard1, Jean Yves Blay, Matthias Schell, Murielle Buclon, Corrine Demaret, Isabelle Ray-Coquard.   

Abstract

PURPOSE: Severe anemias requiring RBC transfusions is a frequent complication of chemotherapy. A model elaborated by Ray-Coquard et al in adults pointed to three independent risk factors for RBC transfusion: performance status (PS) more than 1, hemoglobin less than 12 g/dL, and prechemotherapy absolute lymphocyte count (ALC) < or = 700/microL. This model is tested on a pediatric population. PATIENTS AND METHODS: One hundred nineteen children with solid tumors consecutively admitted for conventional chemotherapy throughout 1 year were included. The study end point was the RBC-transfusion risk in the month following chemotherapy. Only one course was considered for each patient. Age, sex, number of courses, platinum-containing regimens, PS, and hemoglobin and lymphocyte count at day 1 were tested in univariate and multivariate analyses.
RESULTS: Thirty-one (26%) of 119 children required RBC transfusion within 31 days of chemotherapy. Three factors correlated to transfusion risk in the univariate analysis: PS more than 1 (P <.001), hemoglobin less than 12 g/dL (P =.007), and pretreatment ALC < or = 700/microL (P <.001). In the multivariate analysis, hemoglobin less than 12 g/dL, PS more than 1, and ALC < or = 700/microL were identified as independent factors predicting RBC transfusion. The calculated probability of receiving RBC transfusion within 31 days of chemotherapy was high with three risk factors (96%), intermediate with two risk factors (53% to 77%), low with one risk factor (10% to 26%), and very low when no risk factor was present (2%). The difference of transfusion needs was significant (P <.001).
CONCLUSION: The risk model elaborated for adults may also segregate children at high risk of postchemotherapy RBC transfusion, thus facilitating assessment of risk of transfusion and/or prophylactic erythropoietin support.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14615453     DOI: 10.1200/JCO.2003.09.121

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  6 in total

1.  Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas.

Authors:  Isabelle Ray-Coquard; Claire Cropet; Martine Van Glabbeke; Catherine Sebban; Axel Le Cesne; Ian Judson; Olivier Tredan; Jaap Verweij; Pierre Biron; Inthidar Labidi; Jean-Paul Guastalla; Thomas Bachelot; David Perol; Sylvie Chabaud; Pancras C W Hogendoorn; Philippe Cassier; Armelle Dufresne; Jean-Yves Blay
Journal:  Cancer Res       Date:  2009-06-23       Impact factor: 12.701

2.  The efficacy of recombinant human erythropoietin in treatment chemotherapy induced anemia in children diagnosed with a solid cancer.

Authors:  Aa Hiradfar; M Banihosseinian
Journal:  Iran J Ped Hematol Oncol       Date:  2014-12-10

Review 3.  Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines?

Authors:  Christine Ménétrier-Caux; Isabelle Ray-Coquard; Jean-Yves Blay; Christophe Caux
Journal:  J Immunother Cancer       Date:  2019-03-28       Impact factor: 13.751

4.  Trajectories of Lymphocyte Counts in the Early Phase of Acute Pancreatitis Are Associated With Infected Pancreatic Necrosis.

Authors:  Jing Zhou; Wensong Chen; Yang Liu; Cheng Qu; Wendi Jiang; Jiangtao Yin; Jiajia Lin; Wenjian Mao; Bo Ye; Jing Zhou; Lu Ke; Zhihui Tong; Yuxiu Liu; Weiqin Li
Journal:  Clin Transl Gastroenterol       Date:  2021-09-22       Impact factor: 4.488

5.  Anemia and Bone Marrow Suppression After Intra-Arterial Chemotherapy in Children With Retinoblastoma: A Retrospective Analysis.

Authors:  Changjuan Zeng; Minglei Han; Jiayan Fan; Xiaoyu He; Renbing Jia; Li Li; Xuyang Wen; Xuefei Song; Lili Hou
Journal:  Front Oncol       Date:  2022-07-25       Impact factor: 5.738

6.  Pretreatment lymphopenia is an easily detectable predictive and prognostic marker in patients with metastatic esophagus squamous cell carcinoma receiving first-line chemotherapy.

Authors:  Furong Kou; Zhihao Lu; Jian Li; Xiaotian Zhang; Ming Lu; Jun Zhou; Xicheng Wang; Jifang Gong; Jing Gao; Jie Li; Yan Li; Lin Shen
Journal:  Cancer Med       Date:  2016-01-26       Impact factor: 4.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.